Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia
Authors
Keywords
-
Journal
Orphanet Journal of Rare Diseases
Volume 17, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-08
DOI
10.1186/s13023-022-02539-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial
- (2022) Justin P. McWilliams et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma
- (2021) Toshiyuki Seki et al. Scientific Reports
- Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
- (2021) Joseph G. Parambil et al. ANGIOGENESIS
- An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study
- (2020) Hanny Al-Samkari et al. HAEMATOLOGICA
- Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia
- (2020) Marie E. Faughnan et al. ANNALS OF INTERNAL MEDICINE
- Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model
- (2019) Angela M. Crist et al. CIRCULATION
- Circulating angiopoietin-2 and its soluble receptor Tie-2 concentrations are related to inflammatory markers in the general population
- (2018) Elisabeth A. Schuldt et al. CYTOKINE
- Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding
- (2018) Vivek N. Iyer et al. MAYO CLINIC PROCEEDINGS
- Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
- (2018) Marie E. Faughnan et al. ANGIOGENESIS
- Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia
- (2018) Hanny Al-Samkari et al. JOURNAL OF INTERNAL MEDICINE
- Infection prevention in patients with hereditary hemorrhagic telangiectasia
- (2018) Juan Rodríguez-García et al. HAEMATOLOGICA
- Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
- (2017) Alexandre Guilhem et al. PLoS One
- Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding
- (2016) Narendranath Epperla et al. AMERICAN JOURNAL OF HEMATOLOGY
- Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia
- (2016) Kevin J. Whitehead et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia
- (2016) Sophie Dupuis-Girod et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10
- (2016) Santiago Ruiz et al. Scientific Reports
- Executive summary of the 11th HHT international scientific conference
- (2015) Helen Arthur et al. ANGIOGENESIS
- Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia
- (2015) Daniela S. Ardelean et al. Frontiers in Genetics
- VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2
- (2014) Chul Han et al. ANGIOGENESIS
- Seasonal variation and predictors of epistaxis
- (2014) Matthew R. Purkey et al. LARYNGOSCOPE
- Prevalence of Iron Deficiency and Health-related Quality of Life among Female Students
- (2013) Marie-Ange Grondin et al. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
- Lifestyle and Dietary Influences on Nosebleed Severity in Hereditary Hemorrhagic Telangiectasia
- (2013) B. Maneesha Silva et al. LARYNGOSCOPE
- The Complex Role of Angiopoietin-2 in the Angiopoietin-Tie Signaling Pathway
- (2013) G. Thurston et al. Cold Spring Harbor Perspectives in Medicine
- Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output
- (2012) Sophie Dupuis-Girod et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
- (2012) Tanja Holopainen et al. JNCI-Journal of the National Cancer Institute
- Multiple Effects of Angiopoietin-2 Blockade on Tumors
- (2011) Claire E. Lewis et al. CANCER CELL
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia
- (2011) C. Rohrmeier et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- A framework for applying unfamiliar trial designs in studies of rare diseases
- (2011) Samir Gupta et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis
- (2010) Tom T. Karnezis et al. LARYNGOSCOPE
- Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
- (2008) Andrew Mitchell et al. LIVER TRANSPLANTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started